ADMA Biologics, Inc. (ADMA) Reaches $5.41 After 7.00% Up Move; Barnes Group (B) Sentiment Is 1.31

May 17, 2018 - By Peter Erickson

Barnes Group Inc. (NYSE:B) Logo

Barnes Group Inc (B) investors sentiment increased to 1.31 in 2017 Q4. It’s up 0.06, from 1.25 in 2017Q3. The ratio is better, as 114 investment managers increased or opened new stock positions, while 87 sold and trimmed stock positions in Barnes Group Inc. The investment managers in our database reported: 45.52 million shares, down from 45.71 million shares in 2017Q3. Also, the number of investment managers holding Barnes Group Inc in top ten stock positions decreased from 3 to 1 for a decrease of 2. Sold All: 23 Reduced: 64 Increased: 79 New Position: 35.

The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) is a huge mover today! The stock increased 5.46% or $0.28 during the last trading session, reaching $5.41. About 337,325 shares traded or 182.81% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 0.20% since May 17, 2017 and is uptrending. It has underperformed by 11.35% the S&P500.The move comes after 5 months positive chart setup for the $245.17M company. It was reported on May, 17 by We have $5.79 PT which if reached, will make NASDAQ:ADMA worth $17.16M more.

Wooster Corthell Wealth Management Inc. holds 2.44% of its portfolio in Barnes Group Inc. for 73,592 shares. Wasatch Advisors Inc owns 2.06 million shares or 1.73% of their US portfolio. Moreover, Tributary Capital Management Llc has 1.63% invested in the company for 296,858 shares. The Massachusetts-based Aristotle Capital Boston Llc has invested 1.4% in the stock. Ironwood Investment Management Llc, a Massachusetts-based fund reported 30,680 shares.

Another recent and important Barnes Group Inc. (NYSE:B) news was published by which published an article titled: “Barnes’ (B) CEO Patrick Dempsey on Q2 2016 Results – Earnings Call Transcript” on April 27, 2018.

Since January 1, 0001, it had 4 insider buys, and 5 selling transactions for $834,587 activity.

The stock increased 0.28% or $0.17 during the last trading session, reaching $60.43. About 53,507 shares traded. Barnes Group Inc. (B) has risen 19.73% since May 17, 2017 and is uptrending. It has outperformed by 8.18% the S&P500.

Barnes Group Inc. operates as an industrial and aerospace maker and service provider, serving a range of end markets and customers. The company has market cap of $3.18 billion. The firm operates in two divisions, Industrial and Aerospace. It has a 54.69 P/E ratio. The Industrial segment offers precision parts, products, and systems for applications serving various clients in end-markets, such as transportation, industrial equipment, consumer products, packaging, electronics, medical devices, and energy.

Analysts await Barnes Group Inc. (NYSE:B) to report earnings on July, 27. They expect $0.75 EPS, down 7.41% or $0.06 from last year’s $0.81 per share. B’s profit will be $39.44M for 20.14 P/E if the $0.75 EPS becomes a reality. After $0.72 actual EPS reported by Barnes Group Inc. for the previous quarter, Wall Street now forecasts 4.17% EPS growth.

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics had 8 analyst reports since September 9, 2015 according to SRatingsIntel. Raymond James downgraded the stock to “Market Perform” rating in Monday, August 1 report. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. The firm earned “Buy” rating on Thursday, September 17 by Maxim Group. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) has “Buy” rating given on Wednesday, June 28 by Maxim Group. Maxim Group upgraded it to “Buy” rating and $13 target in Monday, January 23 report. The rating was upgraded by Raymond James to “Outperform” on Tuesday, November 14. The firm has “Buy” rating given on Wednesday, June 7 by Maxim Group. The firm earned “Hold” rating on Monday, August 1 by Maxim Group.

Investors sentiment increased to 3 in 2017 Q4. Its up 1.86, from 1.14 in 2017Q3. It improved, as 4 investors sold ADMA Biologics, Inc. shares while 2 reduced holdings. 8 funds opened positions while 10 raised stakes. 15.53 million shares or 121.29% more from 7.02 million shares in 2017Q3 were reported. Northern Tru stated it has 31,405 shares. Fmr Ltd Liability reported 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Morgan Stanley owns 3,774 shares for 0% of their portfolio. Virtu Financial Ltd Co, a New York-based fund reported 23,188 shares. 683 Cap Management Limited Liability Company, New York-based fund reported 950,000 shares. Pennsylvania-based Vanguard Group has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Advisory Service Limited Liability Co owns 700 shares or 0% of their US portfolio. Wells Fargo And Com Mn reported 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Blackrock accumulated 25,421 shares. Perceptive Advisors Ltd Liability Co holds 0.41% or 3.82M shares in its portfolio. Royal Comml Bank Of Canada stated it has 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Iguana Management Limited Com invested 1.25% in ADMA Biologics, Inc. (NASDAQ:ADMA). Moreover, Broadfin Limited Co has 0.58% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 1.10M shares. Goldman Sachs Incorporated reported 0% stake. Prelude Cap Management reported 0.01% stake.

More recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: which released: “ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest” on May 14, 2018. Also published the news titled: “ADMA Biologics Reports First Quarter 2018 Financial Results” on May 14, 2018.‘s news article titled: “ADMA Biologics (ADMA) Retires 8.6M Share” with publication date: May 14, 2018 was also an interesting one.

Barnes Group Inc. (NYSE:B) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: